Actinium Pharmaceuticals (FRA:7AY1) Cyclically Adjusted Book per Share: €3.25 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7AY1 Actinium Pharmaceuticals Inc FRA:7AY1
30 GF Score
Price €0.88
! 4 Warning Signs
View Full Analysis

What is Actinium Pharmaceuticals Cyclically Adjusted Book per Share?

Actinium Pharmaceuticals FRA:7AY1 +4.76% 30 Cyclically Adjusted Book per Share is €3.25 as of Jun. 2026. GuruFocus rates FRA:7AY1 with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Actinium Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2026 was €0.838. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.25 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Actinium Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -31.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -6.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Actinium Pharmaceuticals was 15.80% per year. The lowest was -6.30% per year. And the median was 10.50% per year.

As of today (2026-09-05), Actinium Pharmaceuticals's current stock price is €0.881. Actinium Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €3.25. Actinium Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.27.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Actinium Pharmaceuticals was 2.53. The lowest was 0.18. And the median was 1.05.


Actinium Pharmaceuticals  (FRA:7AY1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Actinium Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.881/3.25
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Actinium Pharmaceuticals was 2.53. The lowest was 0.18. And the median was 1.05.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Actinium Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Actinium Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Actinium Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinium Pharmaceuticals Cyclically Adjusted Book per Share Chart

Actinium Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.28 4.91 5.03 5.90 3.87

Actinium Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.67 4.20 3.87 3.50 3.25

FRA:7AY1 vs NNVC, IGC, KYNB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Actinium Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:7AY1
30GF Score
Actinium Pharmaceuticals Inc FRA:7AY1
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actinium Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Actinium Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.838/333.9520*333.9520
=0.838

Current CPI (Jun. 2026) = 333.9520.

Actinium Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 7.966 241.428 11.019
201612 9.178 241.432 12.695
201703 6.319 243.801 8.656
201706 4.047 244.955 5.517
201709 5.723 246.819 7.743
201712 4.328 246.524 5.863
201803 4.797 249.554 6.419
201806 4.026 251.989 5.336
201809 2.695 252.439 3.565
201812 2.009 251.233 2.670
201903 1.191 254.202 1.565
201906 2.566 256.143 3.345
201909 1.643 256.759 2.137
201912 0.925 256.974 1.202
202003 0.469 258.115 0.607
202006 3.423 257.797 4.434
202009 2.839 260.280 3.643
202012 2.875 260.474 3.686
202103 3.087 264.877 3.892
202106 3.168 271.696 3.894
202109 3.098 274.310 3.772
202112 2.939 278.802 3.520
202203 2.823 287.504 3.279
202206 2.974 296.311 3.352
202209 2.855 296.808 3.212
202212 2.444 296.797 2.750
202303 2.077 301.836 2.298
202306 1.816 305.109 1.988
202309 1.490 307.789 1.617
202312 1.207 306.746 1.314
202403 1.373 312.332 1.468
202406 1.333 314.175 1.417
202409 1.104 315.301 1.169
202412 1.003 315.605 1.061
202503 0.762 319.799 0.796
202506 0.528 322.561 0.547
202509 0.376 324.800 0.387
202512 0.214 324.054 0.221
202603 0.064 330.213 0.065
202606 0.838 333.952 0.838

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €3.25 mean?
Actinium Pharmaceuticals (FRA:7AY1) has a Cyclically Adjusted Book per Share of €3.25 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Actinium Pharmaceuticals and its competitors.
Is Actinium Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Actinium Pharmaceuticals' current Cyclically Adjusted Book per Share is €3.25. Overall, Actinium Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Actinium Pharmaceuticals' Cyclically Adjusted Book per Share compare to NNVC and IGC?
Actinium Pharmaceuticals' Cyclically Adjusted Book per Share of €3.25 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Actinium Pharmaceuticals and its competitors. Actinium Pharmaceuticals's current Cyclically Adjusted Book per Share is €3.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinium Pharmaceuticals stock overvalued right now?
Actinium Pharmaceuticals (FRA:7AY1) has a current Cyclically Adjusted Book per Share of €3.25. The current Cyclically Adjusted Book per Share is €3.25. Actinium Pharmaceuticals' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Actinium Pharmaceuticals (FRA:7AY1), the current Cyclically Adjusted Book per Share is €3.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinium Pharmaceuticals Business Description

Other Exchanges ATNM:USA7AY1:Germany
Address 100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
30GF Score

Get the complete analysis for FRA:7AY1

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price